Increased fluorine-18-flurodeoxyglucose (FDG) uptake in lung cancers has been shown to be a prognostic factor for NSCLC patients, and lower SUV has been reported to be associated with favorable outcomes in EGFR targeted therapy [13]. The gene discussed is EGFR; the disease is lung cancer.